Sales of AbbVie’s blockbuster drug Humira peaked at $18.9bn last year and, according to analysts at Evaluate Pharma, the product is expected to generate $15.2bn through to 2024. These figures are ...
This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...
Even through an onslaught of biosimilar launches that began early last year, AbbVie’s big-selling Humira has been able to retain most of its lucrative market. Still, though, the drug’s star power is ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. When AbbVie’s record-breaking immunology drug Humira came off-patent early last year after generating more than ...
Sept 10 (Reuters) - UnitedHealth Group (UNH.N), opens new tab said on Tuesday it will remove AbbVie’s (ABBV.N), opens new tab blockbuster rheumatoid arthritis drug Humira from some of its lists of ...
Boehringer Ingelheim has decided to reduce its U.S. salesforce as its biosimilars targeting AbbVie's (NYSE:ABBV) blockbuster arthritis therapy, Humira, has lagged expectations, the German drugmaker ...
April 5 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s (ABBV.N), opens new tab blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback